Is There Indication for the Use of Biological Mesh in Cancer Patients?
Up to 28% of all patients who undergo open surgery will develop a ventral hernia (VH) in the post-operative period. VH surgery is a debated topic in the literature, especially in oncological patients due to complex management. We searched in the surgical database of the Hepatobiliary Unit of the Nat...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/20/6035 |
| _version_ | 1797472559629860864 |
|---|---|
| author | Renato Patrone Maddalena Leongito Raimondo di Giacomo Andrea Belli Raffaele Palaia Alfonso Amore Vittorio Albino Mauro Piccirillo Carmen Cutolo Sergio Coluccia Aurelio Nasto Giovanni Conzo Anna Crispo Vincenza Granata Francesco Izzo |
| author_facet | Renato Patrone Maddalena Leongito Raimondo di Giacomo Andrea Belli Raffaele Palaia Alfonso Amore Vittorio Albino Mauro Piccirillo Carmen Cutolo Sergio Coluccia Aurelio Nasto Giovanni Conzo Anna Crispo Vincenza Granata Francesco Izzo |
| author_sort | Renato Patrone |
| collection | DOAJ |
| description | Up to 28% of all patients who undergo open surgery will develop a ventral hernia (VH) in the post-operative period. VH surgery is a debated topic in the literature, especially in oncological patients due to complex management. We searched in the surgical database of the Hepatobiliary Unit of the National Cancer Institute of Naples “G. Pascale Foundation” for all patients who underwent abdominal surgery for malignancy from January 2010 to December 2018. Our surgical approach and our choice of mesh for VH repair was planned case-by-case. We selected 57 patients that fulfilled our inclusion criteria, and we divided them into two groups: biological versus synthetic prosthesis. Anterior component separation was used in 31 patients (54.4%) vs. bridging procedure in 26 (45.6%). In 41 cases (71.9%), we used a biological mesh while a synthetic one was adopted in the remaining patients. Of our patients, 57% were male (33 male vs. 24 female) with a median age of 65 and a mean BMI of 30.8. We collected ventral hernia defects from 35 cm<sup>2</sup> to 600 cm<sup>2</sup> (mean 205.2 cm<sup>2</sup>); 30-day complications were present in 24 patients (42.1%), no 30-day mortality was reported, and 21 patients had a recurrence of pathology during study follow-up. This study confirms VH recurrence risk is not related with the type of mesh but is strongly related with BMI and type of surgery also in oncological patients. |
| first_indexed | 2024-03-09T20:03:09Z |
| format | Article |
| id | doaj.art-b1a652bbf94642a3a6228fa78d97968d |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T20:03:09Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-b1a652bbf94642a3a6228fa78d97968d2023-11-24T00:39:46ZengMDPI AGJournal of Clinical Medicine2077-03832022-10-011120603510.3390/jcm11206035Is There Indication for the Use of Biological Mesh in Cancer Patients?Renato Patrone0Maddalena Leongito1Raimondo di Giacomo2Andrea Belli3Raffaele Palaia4Alfonso Amore5Vittorio Albino6Mauro Piccirillo7Carmen Cutolo8Sergio Coluccia9Aurelio Nasto10Giovanni Conzo11Anna Crispo12Vincenza Granata13Francesco Izzo14Dieti Department, University of Naples Federico II, 80100 Naples, ItalyDivision of Hepatobiliary Surgical Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale—IRCCS di Napoli, 80131 Naples, ItalyDivision of Breast Cancer, Istituto Nazionale Tumori IRCCS Fondazione Pascale—IRCCS di Napoli, 80131 Naples, ItalyDivision of Hepatobiliary Surgical Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale—IRCCS di Napoli, 80131 Naples, ItalyDivision of Hepatobiliary Surgical Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale—IRCCS di Napoli, 80131 Naples, ItalyMelanoma and Skin Cancers Surgery Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale—IRCCS di Napoli, 80131 Naples, ItalyDivision of Hepatobiliary Surgical Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale—IRCCS di Napoli, 80131 Naples, ItalyDivision of Hepatobiliary Surgical Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale—IRCCS di Napoli, 80131 Naples, ItalyDepartment of Medicine, Surgery and Dentistry, University of Salerno, 84084 Salerno, ItalyEpidemiology and Biostatistics Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale—IRCCS di Napoli, 80131 Naples, ItalyDivision of General Surgery, L. Curto Hospital, Polla, 84036 Salerno, ItalyDepartment of Traslational Medical Sciences, University of Campania “Luigi Vanvitelli”, 80131 Naples, ItalyEpidemiology and Biostatistics Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale—IRCCS di Napoli, 80131 Naples, ItalyDivision of Radiology, Istituto Nazionale Tumori IRCCS Fondazione Pascale—IRCCS di Napoli, 80131 Naples, ItalyDivision of Hepatobiliary Surgical Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale—IRCCS di Napoli, 80131 Naples, ItalyUp to 28% of all patients who undergo open surgery will develop a ventral hernia (VH) in the post-operative period. VH surgery is a debated topic in the literature, especially in oncological patients due to complex management. We searched in the surgical database of the Hepatobiliary Unit of the National Cancer Institute of Naples “G. Pascale Foundation” for all patients who underwent abdominal surgery for malignancy from January 2010 to December 2018. Our surgical approach and our choice of mesh for VH repair was planned case-by-case. We selected 57 patients that fulfilled our inclusion criteria, and we divided them into two groups: biological versus synthetic prosthesis. Anterior component separation was used in 31 patients (54.4%) vs. bridging procedure in 26 (45.6%). In 41 cases (71.9%), we used a biological mesh while a synthetic one was adopted in the remaining patients. Of our patients, 57% were male (33 male vs. 24 female) with a median age of 65 and a mean BMI of 30.8. We collected ventral hernia defects from 35 cm<sup>2</sup> to 600 cm<sup>2</sup> (mean 205.2 cm<sup>2</sup>); 30-day complications were present in 24 patients (42.1%), no 30-day mortality was reported, and 21 patients had a recurrence of pathology during study follow-up. This study confirms VH recurrence risk is not related with the type of mesh but is strongly related with BMI and type of surgery also in oncological patients.https://www.mdpi.com/2077-0383/11/20/6035ventral herniaoncological patientsventral hernia repairabdominal wallmeshbiological mesh |
| spellingShingle | Renato Patrone Maddalena Leongito Raimondo di Giacomo Andrea Belli Raffaele Palaia Alfonso Amore Vittorio Albino Mauro Piccirillo Carmen Cutolo Sergio Coluccia Aurelio Nasto Giovanni Conzo Anna Crispo Vincenza Granata Francesco Izzo Is There Indication for the Use of Biological Mesh in Cancer Patients? Journal of Clinical Medicine ventral hernia oncological patients ventral hernia repair abdominal wall mesh biological mesh |
| title | Is There Indication for the Use of Biological Mesh in Cancer Patients? |
| title_full | Is There Indication for the Use of Biological Mesh in Cancer Patients? |
| title_fullStr | Is There Indication for the Use of Biological Mesh in Cancer Patients? |
| title_full_unstemmed | Is There Indication for the Use of Biological Mesh in Cancer Patients? |
| title_short | Is There Indication for the Use of Biological Mesh in Cancer Patients? |
| title_sort | is there indication for the use of biological mesh in cancer patients |
| topic | ventral hernia oncological patients ventral hernia repair abdominal wall mesh biological mesh |
| url | https://www.mdpi.com/2077-0383/11/20/6035 |
| work_keys_str_mv | AT renatopatrone isthereindicationfortheuseofbiologicalmeshincancerpatients AT maddalenaleongito isthereindicationfortheuseofbiologicalmeshincancerpatients AT raimondodigiacomo isthereindicationfortheuseofbiologicalmeshincancerpatients AT andreabelli isthereindicationfortheuseofbiologicalmeshincancerpatients AT raffaelepalaia isthereindicationfortheuseofbiologicalmeshincancerpatients AT alfonsoamore isthereindicationfortheuseofbiologicalmeshincancerpatients AT vittorioalbino isthereindicationfortheuseofbiologicalmeshincancerpatients AT mauropiccirillo isthereindicationfortheuseofbiologicalmeshincancerpatients AT carmencutolo isthereindicationfortheuseofbiologicalmeshincancerpatients AT sergiocoluccia isthereindicationfortheuseofbiologicalmeshincancerpatients AT aurelionasto isthereindicationfortheuseofbiologicalmeshincancerpatients AT giovanniconzo isthereindicationfortheuseofbiologicalmeshincancerpatients AT annacrispo isthereindicationfortheuseofbiologicalmeshincancerpatients AT vincenzagranata isthereindicationfortheuseofbiologicalmeshincancerpatients AT francescoizzo isthereindicationfortheuseofbiologicalmeshincancerpatients |